London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that positive phase 2a data supporting the development of OncoGelTM in oesophageal cancer were presented yesterday during a poster session at the Digestive Disease Week (“DDW”) 2007 Conference in Washington, DC. The poster was selected as a “Poster of Distinction,” placing it in the top 10% of all American Gastroenterology Association (AGA) Institute abstracts selected for poster presentation.
